|Articles|February 14, 2023

Suprachoroidal Triamcinolone Acetonide Injectable Suspension for Macular Edema Associated With Noninfectious Uveitis: An In-Depth Look at Efficacy and Safety

Participating Faculty: Suprachoroidal Triamcinolone Acetonide Injectable Suspension for Macular Edema Associated With Noninfectious Uveitis: An In-Depth Look at Efficacy and Safety

Author(s)Steven Yeh, MD, Thomas Ciulla, MD, MBA

Faculty

Steven Yeh, MD

Professor of Ophthalmology & Director of the Retina and Uveitis Service

Truhlsen Eye Institute

University of Nebraska Medical Center

Omaha, NE

Thomas Ciulla, MD, MBA

Chief Medical Officer & Chief Development Officer

Clearside Biomedical

Alpharetta, GA

Volunteer Clinical Professor

Indiana University School of Medicine

Indianapolis, Indiana

Faculty Disclosures

These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.

Steven Yeh, MD

CONSULTANCIES OR PAID ADVISORY BOARDS

Bausch + Lomb, Adverum Biotechnologies, REGENXBIO

Thomas Ciulla, MD, MBA

STOCK OWNERSHIP

Clearside Biomedical

EMPLOYMENT

Clearside Biomedical

Articles in this issue

over 3 years ago

Article

Suprachoroidal Triamcinolone Acetonide Injectable Suspension for Macular Edema Associated With Noninfectious Uveitis: An In-Depth Look at Efficacy and Safety

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Participating Faculty: Suprachoroidal Triamcinolone Acetonide Injectable Suspension for Macular Edema Associated With Noninfectious Uveitis: An In-Depth Look at Efficacy and Safety

Faculty

Steven Yeh, MD

Thomas Ciulla, MD, MBA

Faculty Disclosures

Steven Yeh, MD

Thomas Ciulla, MD, MBA

Articles in this issue

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

From CAR T-Cell Therapy to ADCs: Tackling Oncology Access Gaps

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

Participating Faculty: Suprachoroidal Triamcinolone Acetonide Injectable Suspension for Macular Edema Associated With Noninfectious Uveitis: An In-Depth Look at Efficacy and Safety

Faculty

Steven Yeh, MD

Thomas Ciulla, MD, MBA

Faculty Disclosures

Steven Yeh, MD

Thomas Ciulla, MD, MBA

Articles in this issue

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

From CAR T-Cell Therapy to ADCs: Tackling Oncology Access Gaps

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%